Jaguar动物健康 JAGX 深 沪
交易中 09-04 11:21:06 美东时间
1.63
-0.050
-2.98%
华盛通- 最 高1.68
- 今 开1.68
- 成交量 2.04万股
- 最 低 1.63
- 昨 收 1.68
- 总市值 206.15万
- 52周最高 35.25
- 市盈率 静 --
- 换手率 1.61%
- 52周最低 1.5701
- 委 比 -37.43%
- 总股本 126.47万
- 历史最高 2501887500.00
- 量 比 0.38
- 振 幅 2.98%
- 历史最低 1.63
- 每 手 1
- 风险率 10.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jaguar Health's Canalevia-CA1 Conditionally FDA-Approved For Canine Chemotherapy-Induced Diarrhea; Enrollment Has Reached ~25%; Seeks Partnerships To Expand Indication To General Diarrhea In Dogs
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogsCompany strategy: In discussions with multiple potential animal
08-21 21:05
Jaguar Health Announces Promising Trial Results
An announcement from Jaguar Animal Health ( ($JAGX) ) is now available. On Augu...
08-20 04:49
Jaguar Health Reports Increased Losses Amid Rising Expenses
Jaguar Animal Health Inc. ( ($JAGX) ) has released its Q2 earnings. Here is a b...
08-15 12:19
Jaguar Health Extends Market Offering Agreement
Jaguar Animal Health ( ($JAGX) ) just unveiled an update. On August 14, 2025, J...
08-14 21:58
Jaguar Health shares are trading lower after the company reported worse-than-expected Q2 financial results.
Jaguar Health shares are trading lower after the company reported worse-than-ex...
08-14 20:53
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
Earnings Preview For Jaguar Health
Jaguar Health (NASDAQ:JAGX) is gearing up to announce its quarterly earnings on...
08-14 02:03
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
Jaguar Animal Health Issues Series M Preferred Stock
Jaguar Animal Health ( ($JAGX) ) has provided an announcement. On June 27, 2025...
07-01 03:49
Jaguar Health's Napo Announces That Initial Proof-Of-Concept Results From Ongoing IIT Show Liquid Formulation Of Crofelemer Reduced Required TPN And Supplementary Intravenous Fluids In Third Intestinal Failure Patient
As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus
06-30 21:23
